Amgen showcases its last big round of promising KRAS G12C data for sotorasib. Next up: A likely marketing campaign for a breakthrough therapy

Amgen is showing off the last, breakthrough round of data it has from the pivotal study for its KRAS G12C drug sotorasib in non-small cell lung cancer — the data they’ll be going to market with, if regulators come through with an accelerated OK soon, which is widely expected. The…

Click to view original post